statement
IMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
IMVT-1402가 Batoclimab 대비 고콜레스테롤혈증 우려 없이 지속적인 고용량 투약이 가능함을 임상적으로 입증한 첫 사례
Related claims
Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementLG Chem signed a revised license agreement with Rhythm Pharmaceuticals for Bivamelagon on November 3, expanding total contract value from $305 million to $855 million.LG화학 · statementЭтим препаратам нет аналога.Голикова · statement